The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting increased shareholder activism within the med-tech sector, Steel Partners Holdings L.P. has issued a formal letter to the Board of Directors of InMode Ltd. The firm, identifying itself as a significant and long-standing shareholder, initiated this communication to address the company's strategic direction. While specific demands were not detailed in the initial reports, the move places the board under direct scrutiny from its institutional investor base.
This pressure comes as InMode navigates a challenging environment; the company reported a 5% year-over-year revenue decline in its most recent quarterly results according to corporate filings. Compared to peers in the medical aesthetics space, such as Cutera (CUTR) which has faced similar pricing headwinds, Steel Partners likely aims to ensure disciplined capital allocation. InMode's market valuation has experienced significant volatility over the past year per market data.
Regarding market performance, INMD shares stood at $15.28 (at close July 15, 2026), having traded between a day low of $14.86 and a high of $15.36. Investors are now watching for a formal response from InMode's board or further disclosures from Steel Partners regarding their proposals, while also monitoring the Fed's Monetary Policy Report on July 10, 2026, for broader sector financing implications.